Phase II clinical trial - VADS

ICING ORL
VADS
Ouvert depuis le: 09.28.2021
Site: Paris
Public cible
Adulte
A Phase II Trial Assessing Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-ß and PD-L1, in a Pre-operative Setting for Resectable and Untreated Head and Neck Squamous Cell Carcinoma
Description de l'essai

This study is a prospective open label, multicenter, phase II, window-of-opportunity preoperative, single-agent trial.;This study aims to evaluate the efficacy, the safety and tolerability profile of bintrafusp alfa in patients with histologically or cytologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, larynx or hypopharynx, previously untreated, with indication of primary surgery. Patients with a diagnosis of head and neck squamous cell carcinoma (HNSCC) from unknown primary will not be enrolled.